No­var­tis wash­es its hands of an­oth­er bis­pe­cif­ic at the cen­ter of $2.5B Xen­cor deal

A cen­ter­piece of No­var­tis’ $2.5 bil­lion bis­pecifics deal with Xen­cor has been side­lined, the Cal­i­for­nia biotech said in its third quar­ter earn­ings re­port Mon­day.

No­var­tis ter­mi­nat­ed its ex-US rights to the pro­gram dubbed vibeco­tam­ab, a bis­pe­cif­ic tar­get­ing CD123 and CD3 for acute myeloid leukemia. The move will take ef­fect next Feb­ru­ary, Xen­cor said Mon­day. Xen­cor will drop de­vel­op­ment of the drug al­to­geth­er as well, say­ing it has no fu­ture plans for in-house re­search.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER